CN1174971C - 吗啉醚 - Google Patents

吗啉醚 Download PDF

Info

Publication number
CN1174971C
CN1174971C CNB998085146A CN99808514A CN1174971C CN 1174971 C CN1174971 C CN 1174971C CN B998085146 A CNB998085146 A CN B998085146A CN 99808514 A CN99808514 A CN 99808514A CN 1174971 C CN1174971 C CN 1174971C
Authority
CN
China
Prior art keywords
methyl
substituted
group
alkoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998085146A
Other languages
English (en)
Chinese (zh)
Other versions
CN1309651A (zh
Inventor
J・M・比诺
J·M·比诺
槁薰痹洛
J·赤查罗贡扎洛
科特容
J·M·科特容
赛瓦斯
J·C·赛瓦斯
费安多尔
J·M·费安多尔
A·马洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Wellcome SA
Original Assignee
Glaxo Wellcome SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome SA filed Critical Glaxo Wellcome SA
Publication of CN1309651A publication Critical patent/CN1309651A/zh
Application granted granted Critical
Publication of CN1174971C publication Critical patent/CN1174971C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
CNB998085146A 1998-05-11 1999-05-07 吗啉醚 Expired - Fee Related CN1174971C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98500117.1 1998-05-11
EP98500117 1998-05-11
EP98500204.7 1998-09-18
EP98500204 1998-09-18

Publications (2)

Publication Number Publication Date
CN1309651A CN1309651A (zh) 2001-08-22
CN1174971C true CN1174971C (zh) 2004-11-10

Family

ID=26151831

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998085146A Expired - Fee Related CN1174971C (zh) 1998-05-11 1999-05-07 吗啉醚

Country Status (13)

Country Link
EP (1) EP1077959A1 (fr)
JP (1) JP2002514632A (fr)
KR (1) KR100625146B1 (fr)
CN (1) CN1174971C (fr)
AR (1) AR016261A1 (fr)
AU (1) AU763088B2 (fr)
BR (1) BR9910377A (fr)
CA (1) CA2331584A1 (fr)
MA (1) MA26628A1 (fr)
PE (1) PE20000479A1 (fr)
TR (1) TR200003301T2 (fr)
TW (1) TW585858B (fr)
WO (1) WO1999058512A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001286208A1 (en) * 2000-09-13 2002-03-26 Sankyo Company Limited Zofimarin derivatives having oxazepam ring
RU2259825C9 (ru) * 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
CA2975371C (fr) * 2015-01-30 2024-02-13 Nof Corporation Lipide cationique pour l'administration d'acide nucleique

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH465771A (de) * 1965-12-06 1968-11-30 Sandoz Ag Verfahren zur Herstellung eines neuen Antibioticums
JPH0615555B2 (ja) * 1985-08-14 1994-03-02 三共株式会社 抗生物質ゾフイマリン
US5854280A (en) * 1994-11-08 1998-12-29 Glaxo Wellcome S.A. Antifungal sordaridin derivatives
EP0711783A1 (fr) * 1994-11-08 1996-05-15 Glaxo, S.A. Dérivés de Sordarin antifongiques
EP0711784A1 (fr) * 1994-11-08 1996-05-15 Glaxo, S.A. Dérivés de Sordarin antifongiques
EP0712859A1 (fr) * 1994-11-08 1996-05-22 Glaxo, S.A. Dérivés de Sordarin antifongiques
EP0901493A1 (fr) * 1996-05-08 1999-03-17 Glaxo Wellcome S.A. Procede de preparation d'un compose d'indacene
WO1998011891A1 (fr) * 1996-09-18 1998-03-26 Merck & Co., Inc. Sordarine et derives de sordarine a utiliser comme agents antifongiques dans les cultures vegetales
ES2215220T3 (es) * 1996-10-07 2004-10-01 MERCK & CO., INC. Derivados de sordarina.
NZ502763A (en) * 1997-08-22 2002-03-28 Merck & Co Inc 4-cyano-4-deformylsordarin derivatives
DE69813833T2 (de) * 1997-08-22 2004-01-15 Merck & Co Inc 4-cyano-4-deformylsordarizin-derivate

Also Published As

Publication number Publication date
KR20010025009A (ko) 2001-03-26
CN1309651A (zh) 2001-08-22
TR200003301T2 (tr) 2001-02-21
TW585858B (en) 2004-05-01
AU763088B2 (en) 2003-07-10
CA2331584A1 (fr) 1999-11-18
BR9910377A (pt) 2001-01-16
JP2002514632A (ja) 2002-05-21
AU4258899A (en) 1999-11-29
PE20000479A1 (es) 2000-05-29
EP1077959A1 (fr) 2001-02-28
MA26628A1 (fr) 2004-12-20
AR016261A1 (es) 2001-06-20
WO1999058512A1 (fr) 1999-11-18
KR100625146B1 (ko) 2006-09-20

Similar Documents

Publication Publication Date Title
CN1310907C (zh) 杂环化合物和以其为有效成分的抗肿瘤药
CN1075812C (zh) 吗啉速激肽受体拮抗剂的前药
CN1185230C (zh) N－取代的氨基甲酰氧基烷基－吡咯鎓衍生物
HK1049118A1 (zh) 金属蛋白酶抑制剂
CN1067655A (zh) 含氮杂环类化合物的氟代烷氧基苄氨基衍生物
CN1087902A (zh) 吗啉和硫代吗啉速激肽受体拮抗药
CN1809568A (zh) 作为dpp－iv抑制剂的吡啶并2,1－a－异喹啉衍生物
CN1349503A (zh) 肾素抑制剂
CN1083062A (zh) 异羟肟酸衍生物
CN1192143A (zh) 2－(1h－4(5)－咪唑基环丙基衍生物
CN1073944A (zh) 三取代四氢呋喃抗真菌剂
CN1681801A (zh) 喹啉基丙基哌啶衍生物以及其作为抗微生物剂的应用
CN1067889A (zh) 取代的n-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺的制备方法
CN1662549A (zh) 治疗代谢紊乱的糖皮质激素受体配基
CN1025500C (zh) 杂芳基3-氧-丙腈衍生物的制备方法
CN1033325C (zh) 抗炎异羟肟酸和n-羟基脲的制备方法
CN1154483C (zh) 胺化合物用于制备阻止肿瘤细胞增殖的药物
CN1278262A (zh) 三环三唑并苯并氮杂衍生物、用于制备该衍生物的方法和抗变态反应剂
CN101048393A (zh) 作为γ－分泌酶抑制剂的取代的N－芳基磺酰基杂环胺
CN1093536C (zh) 5－脂肪氧合酶抑制剂
CN1059336A (zh) 抗真菌的三唑衍生物及其制备和用途
CN1054980A (zh) 具有旋光活性的8-甲氧基喹诺酮羧酸衍生物，它们的制备方法以及它们的中间体
CN1174971C (zh) 吗啉醚
CN1199960C (zh) 新的沉香呋喃衍生物,它们的制备方法,含它们的药物组合物及它们作为药物的用途
CN1273463C (zh) (1－苯甲酰甲基－3－苯基－3－哌啶基乙基)哌啶衍生物,制备它们的方法以及包含它们的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1071346

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee